Exploration of immune-mediated inflammatory diseases post COVID-19 vaccination reveals lack of information and potential issues.
-
Focus on vaccine vasculitis and autoimmune response triggered by COVID-19 vaccination. • 0:04
-
Importance of cautious immune system stimulation during pandemic. • 0:32
-
Discussion of recent paper on new onset rheumatic immune inflammatory diseases post vaccination. • 1:06
-
Concerns raised about lack of information on immune-mediated inflammatory diseases post COVID-19 vaccination. • 3:06
Investigating potential vaccine-related vasculitis and its implications.
-
271 cases from 39 countries between January 2021 and May 2023 were studied for vasculitis • 3:58
-
Concern over the possibility of autoimmune reactions to mRNA vaccines • 4:44
-
Autoimmune vasculitis targets blood vessels through immune system response • 6:02
-
Different types of vasculitis can damage blood vessels in various ways • 6:36
-
Damage to blood vessel lining leads to inflammation, a critical aspect of vasculitis • 7:26
Potential risks of vaccine-induced vasculitis and overlooked autoimmune response in COVID-19 vaccines.
-
Damage to blood vessel lining can lead to clot formation, causing blockages and issues with blood flow. • 7:56
-
Severe COVID-19 described as lung vasculitis, leading to micro thrombi and blockages in the lungs. • 9:05
-
Autoimmune response may target normal proteins due to mimicry with spike proteins, posing a risk with vaccines. • 10:03
-
Scientific community may have overlooked autoimmune response in vaccine development. • 10:37
-
Study demographics included patients from Japan, India, Turkey, China, and South Korea receiving various vaccines. • 10:55
Exploring potential risks of vaccine-induced vasculitis and the need for further investigation.
-
Vaccine-induced vasculitis may be associated with spike proteins from various vaccines. • 11:14
-
Different vaccines have varying rates of vasculitis, with Pfizer having the highest reported cases. • 11:31
-
Limited systematic reviews on post-vaccination inflammatory diseases highlight gaps in understanding. • 12:48
-
Onset of symptoms after vaccination is short-lived, with most cases responding to steroids. • 14:23
-
Current cases of vaccine-induced vasculitis are considered rare and manageable with treatment. • 14:58
-
There is a need for further research to determine the significance and implications of vaccine-induced vasculitis. • 15:16
Potential discovery of autoimmune response post mRNA vaccines raises concerns for future health implications.
-
Study found 28.57% of healthcare workers developed autoantibodies after receiving Pfizer vaccines. • 15:34
-
Increased levels of autoantibodies observed in individuals with pre-existing autoimmune conditions. • 16:38
-
Concerns raised about potential long-term autoimmune vasculitis development. • 16:46
-
Lack of incentive to investigate potential vaccine-related autoimmune responses. • 17:05
-
Limited understanding hinders opportunities for mitigation of health risks. • 17:15
-
Even a small percentage of population affected could have significant global health implications. • 17:33
-
Continued exploration of COVID-19 vaccine-induced autoimmunity is crucial for public health. • 17:45